| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| Other Sizes |
|
| ln Vitro |
In MRC-5 cells, 8-hydroxyquinoline (8HQ) (Compd 1) exhibits cytotoxicity with an IC50 of 6.27 μM[1]. When combined with CuCl2, 10.0 μM, for one hour, 8-hydroxyquinoline (8-OHQ) (Compd 1) creates a complex with copper that facilitates copper transport into human breast cancer DCIS cells [2]. When 8-hydroxyquinoline is combined with CuCl2, 0–20.0 μM, it binds to copper and produces a complex that has tyrosine kinase inhibitor-like activity (1–5 μM, 2–12 hours)[2]. causes time- and dose-dependent cell death in DCIS cells [2]. In Raw 264.7 cells, hydroxyquinoline (0-100 μM, 30 minutes) suppresses regulatory factors by blocking NO generation and iNOS expression through the activation of NF-κB and decreasing C/EBPb DNA-binding activity [3].
|
|---|---|
| ln Vivo |
In CD1 mice, a single intraperitoneal injection of 8-hydroxyquinoline (HOQ) at a dose of 25–100 mg/kg significantly increases the quantity of micronucleated polychromatic erythrocytes (MPCE) [4]. Hair growth and loss are caused by 8-Hydroxyquinoline (8-HQ) (0.3%, Skin Appearance, 4 times weekly), with growth patterns altering over time [5].
|
| Cell Assay |
Cell Viability Assay[2]
Cell Types: DCIS Cell Tested Concentrations: 1, 2.5, 5, 10, 20 μM Incubation Duration: 1 or 8 hrs (hours) Experimental Results: Binds to copper and forms a complex, causing cells to agglomerate and separate, at a certain concentration and Induces cell death in a time-dependent manner. 8-OHQ- and CQ-Cu, but not their analogs and mixtures of Cu, can induce cancer cell death in a concentration- and time-dependent manner. Western Blot Analysis[2] Cell Types: DCIS Cell Tested Concentrations: 1, 2.5, 5 μM Incubation Duration: 0, 2, 4, 8, 12 hrs (hours) Experimental Results: CuCl2 mixture inhibited CT-like activity in a concentration and time dependent manner. Mixtures of CuCl2 diminished proteasome activity and increased accumulation of ubiquitinated proteins and Bax in a time-dependent manner. RT-PCR[3] Cell Types: Lipopolysaccharide-stimulated original 264.7 cells Tested Concentrations: 25, 50, 75, 100 μM Incubation Duration: 30 minutes Experimental Results: Inhibited of LPS-induced NO and iNOS expression.br/> Inhibits transcription of iNOS. Had not affect phosphorylation of MAPKs. Inhibited NF-jB-binding activity and C/EBPb-binding activity. |
| Animal Protocol |
Animal/Disease Models: CD1 mice[4]
Doses: 25,50,100 mg/kg Route of Administration: intraperitoneal (ip) injection Experimental Results: All doses tested resulted in micronucleated polychromatic erythrocytes (MPCE) numbers over a 24-hour sampling period Significant dose-related increase. Animal/Disease Models: C57BL mice [5] Doses: 0.3% Administration 4 times a week: Dermal administration Experimental Results: Causes depigmented hair to grow in a time-varying manner. Frequent enough use results in nearly complete depigmentation in young adult C57BL female mice, whereas a single application results in isolated bands of depigmented hair. |
| References |
[1]. Lawung R, et.al. Repositioning of 8-hydroxyquinoline derivatives as a new promising candidate for combating multidrug resistant Neisseria gonorrhoeae. EXCLI J. 2018 Aug 23;17:840-846.
[2]. 8-hydroxyquinoline and clioquinol requires their capabilities to bind copper and transport copper into cells. J Biol Inorg Chem. 2010 Feb;15(2):259-69. [3]. Zhai S, et.al. Tumor cellular proteasome inhibition and growth suppression by [4]. Hamoud MA, et.al. Effects of quinoline and 8-hydroxyquinoline on mouse bone marrow erythrocytes as measured by the micronucleus assay. Teratog Carcinog Mutagen. 1989;9(2):111-8. [5]. Searle CE. The selective depigmenting action of 8-hydroxyquinoline on hair growth in the mouse. Br J Dermatol. 1972 May;86(5):472-80. |
| Molecular Formula |
C9H7O
|
|---|---|
| Molecular Weight |
145.16
|
| Exact Mass |
145.0528
|
| CAS # |
148-24-3
|
| Related CAS # |
8-Hydroxyquinoline hemisulfate;134-31-6
|
| Appearance |
Typically exists as solids (or liquids in special cases) at room temperature
|
| SMILES |
O([H])C1=C([H])C([H])=C([H])C2C([H])=C([H])C([H])=NC=21
|
| Synonyms |
NSC-2039; NSC 2039; Oxyquinoline
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~50 mg/mL (~344.45 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (17.22 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (17.22 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (17.22 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 6.8890 mL | 34.4448 mL | 68.8895 mL | |
| 5 mM | 1.3778 mL | 6.8890 mL | 13.7779 mL | |
| 10 mM | 0.6889 mL | 3.4445 mL | 6.8890 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
